StreetInsider.com News Articles

Form DEF 14A Sonoma Pharmaceuticals, For: Jun 24

Tue, 05 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260505/26436117.html

Form DEF 14A Sonoma Pharmaceuticals, For: Jun 24

Tue, 05 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260505/26436117.html

Form 8-K Sonoma Pharmaceuticals, For: Apr 24

Thu, 30 Apr 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260430/26409780.html

Form 8-K Sonoma Pharmaceuticals, For: Apr 24

Thu, 30 Apr 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260430/26409780.html

Form 424B4 Sonoma Pharmaceuticals,

Mon, 27 Apr 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260427/26369161.html

Form 424B4 Sonoma Pharmaceuticals,

Mon, 27 Apr 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260427/26369161.html

Form PRE 14A Sonoma Pharmaceuticals, For: Apr 24

Mon, 27 Apr 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260427/26369121.html

Form PRE 14A Sonoma Pharmaceuticals, For: Apr 24

Mon, 27 Apr 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260427/26369121.html

Sonoma Pharmaceuticals prices $4 million public offering at $1.35 per share

Fri, 24 Apr 2026 09:23:12 -0400

Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) announced the pricing of its public offering with expected gross proceeds of approximately $4 million before fees and expenses. The offering consists of 2,962,963 shares of common stock and 2,962,963 warrants, with each share priced at $1.35.

The warrants carry an exercise price of $1.35 per share. Sonoma Pharmaceuticals granted Dawson James Securities a 45-day option to purchase up to 15% of the shares or warrants sold to cover over-allotments.

The offering is scheduled to close on April 27, 2026, subject to customary closing conditions. The company plans to use net proceeds for general corporate purposes, including

Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering

Fri, 24 Apr 2026 09:21:00 -0400

BOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. (the "Company" or "Sonoma Pharmaceuticals") (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the pricing of its public offering made on a firm commitment basis with gross proceeds to the Company expected to be approximately $4.0 million, before deducting fees and other expenses payable by the Company. The offering consists of 2,962,963 shares of common stock and 2,962,963 warrants. Each share of common stock is being sold at a purchase price of $1.35 per share.

Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering

Fri, 24 Apr 2026 09:21:00 -0400

Form EFFECT Sonoma Pharmaceuticals,

Fri, 24 Apr 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260424/26361827.html

Form EFFECT Sonoma Pharmaceuticals,

Fri, 24 Apr 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260424/26361827.html

Form S-1/A Sonoma Pharmaceuticals,

Thu, 23 Apr 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260423/26353880.html

Form S-1/A Sonoma Pharmaceuticals,

Thu, 23 Apr 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260423/26353880.html

Form S-1 Sonoma Pharmaceuticals,

Fri, 17 Apr 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260417/26331735.html

Form S-1 Sonoma Pharmaceuticals,

Fri, 17 Apr 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260417/26331735.html

Form 8-K Sonoma Pharmaceuticals, For: Apr 08

Thu, 09 Apr 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260409/26292710.html

Form 8-K Sonoma Pharmaceuticals, For: Apr 08

Thu, 09 Apr 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260409/26292710.html

Sonoma Pharmaceuticals launches burn relief hydrogel in CVS and Walmart

Tue, 24 Mar 2026 08:33:06 -0400

Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) launched its hypochlorous acid-based burn relief hydrogel in CVS and Walmart stores nationwide. The product targets management of minor burns and skin irritations.

The hydrogel represents Sonoma's first large-scale consumer burn relief product. The company previously launched a diaper rash hydrogel in mass retail in 2025 and maintains an established presence in professional healthcare settings with its hypochlorous acid solutions.

The product is being commercialized through a U.S.-based partner that distributes through CVS and Walmart. This approach aligns with Sonoma's strategy to leverage partnerships for retail expansion.

"We are excited to expand further into the consumer over-the-counter market

Sonoma Pharmaceuticals launches burn relief hydrogel in CVS and Walmart

Tue, 24 Mar 2026 08:33:06 -0400

The product is being commercialized through a U.S.-based partner that distributes through CVS and Walmart. This approach aligns with Sonoma's strategy to leverage partnerships for retail expansion.

"We are excited to expand further into the consumer over-the-counter market

Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

Tue, 24 Mar 2026 08:30:00 -0400

BOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart stores nationwide.

The hydrogel is indicated for the management of minor burns and skin irritations. Its gentle, non-irritating formulation is designed to help soothe damaged skin and support the natural healing process, making it well-suited for everyday consumer use, including seasonal sunburn care.

This launch represents Sonoma's first large-scale consumer-focused burn relief product, building

Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

Tue, 24 Mar 2026 08:30:00 -0400

This launch represents Sonoma's first large-scale consumer-focused burn relief product, building

Sonoma Pharmaceuticals launches Aquanil AD skin care line

Wed, 18 Mar 2026 08:32:09 -0400

Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) announced the launch of Aquanil AD, a dermatology product line developed for Persōn & Covey Inc. for distribution through over-the-counter channels in the United States.

The product line includes three items targeting sensitive skin: Aquanil AD Repair Mist for irritated or damaged skin, Aquanil AD Recovery Gel designed to reduce scar appearance, and Aquanil AD Rescue Serum for rashes, itching and irritation relief. All products use Sonoma's Microcyn technology based on stabilized hypochlorous acid.

"The incomparable safety profile of Sonoma's Microcyn technology made it an ideal choice for our Aquanil line and our commitment to providing relief

Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin

Wed, 18 Mar 2026 08:30:00 -0400

BOULDER, CO / ACCESS Newswire / March 18, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn^® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced the launch of Aquanil^® AD, a hypochlorous acid based dermatology product line for sensitive skin, developed exclusively for Persōn & Covey, Inc. for distribution through its established over-the-counter dermatology channels in the United States.

The Aquanil AD product